Cephalexin is NOT an optimal choice for lower respiratory tract infections
Cephalexin should generally be avoided as first-line therapy for LRTI because it lacks adequate coverage against Haemophilus influenzae, a key pathogen in these infections. 1, 2
Why Cephalexin Falls Short
While the FDA label indicates cephalexin is approved for respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes 3, this narrow spectrum is insufficient for most LRTIs in clinical practice. The critical limitation is its poor activity against H. influenzae, which is a major pathogen in:
- Acute exacerbations of COPD
- Community-acquired pneumonia
- Acute bronchitis in adults with chronic lung disease
Research confirms this weakness: "Resistance of H. influenzae strains reduces the uses of cephalexin in the paediatric population and may limit its effectiveness in some patients with acute exacerbations of chronic bronchitis" 4.
What You Should Use Instead
For Home-Managed LRTI (Outpatient):
First-line choice: Amoxicillin 1, 2
- Covers both S. pneumoniae and H. influenzae
- Proven efficacy with extensive clinical experience
- Low cost
Alternative if high local β-lactamase-producing H. influenzae:
- Amoxicillin-clavulanate 1
- Oral second-generation cephalosporin (e.g., cefuroxime-axetil) - but NOT cephalexin 1, 5
If penicillin allergy or recent aminopenicillin failure:
- Tetracycline (also covers atypical pathogens) 2
- Macrolide (only in areas with low pneumococcal resistance) 1, 2
- Respiratory fluoroquinolone (levofloxacin, moxifloxacin) as second-line 2
For Hospital-Managed LRTI:
- Second or third-generation cephalosporins (cefuroxime, ceftriaxone, cefotaxime) 1
- These have broader spectrum than cephalexin
Treatment Duration
Common Pitfall to Avoid
Do not assume all oral cephalosporins are equivalent. Cephalexin is a first-generation cephalosporin with limited gram-negative coverage. When guidelines recommend "oral cephalosporin" for LRTI, they specifically mean second or third-generation agents (cefuroxime-axetil, cefpodoxime-proxetil), NOT cephalexin 1, 5.
The 2011 European guidelines explicitly state that oral cephalosporins "do not have a clear added value" over amoxicillin for LRTI 2, and when they are used, it should be the newer generations with H. influenzae coverage.
When Cephalexin Might Be Acceptable
The only scenario where cephalexin could be considered is in confirmed streptococcal pharyngitis with lower respiratory symptoms where S. pyogenes is the documented pathogen 3. However, even then, penicillin remains the drug of choice 1.